[1] SUGIMOTO H,SHINKYO R,HAYASHI K,et al.Crystal structure of CYP105A1(P450SU-1) in complex with 1α,25-dihydroxyvitamin D
3[J].Biochemistry,2008,47(13):4017-4027.
[2] TOXQUI L,VAQUERO M P.Chronic iron deficiency as an emerging risk factor for osteoporosis:a hypothesis[J].Nutrients,2015,7(4):2324-2344.
[3] ITO M,SAKAI Y,FURUMOTO M,et al.Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells[J].American Journal of Physiology-Endocrinology and Metabolism,2005,288(6):E1101-E1109.
[4] MEIR T,DURLACHER K,PAN Z,et al.Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription[J].Kidney International,2014,86(6):1106-1115.
[5] LAVI-MOSHAYOFF V,WASSERMAN G,MEIR T,et al.PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure:a bone parathyroid feedback loop[J].American Journal of Physiology.Renal Physiology,2010,299(4):F882-F889.
[6] BACIC D,LEHIR M,BIBER J,et al.The renal Na
+/phosphate cotransporter NaPi-Ⅱa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone[J].Kidney International,2006,69(3):495-503.
[7] SHIMADA T,HASEGAWA H,YAMAZAKI Y,et al.FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis[J].Journal of Bone and Mineral Research,2004,19(3):429-435.
[8] SHIMADA T,MIZUTANI S,MUTO T,et al.Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia[J].Proceedings of the National Academy of Sciences of the United States of America,2001,98(11):6500-6505.
[9] DAVID V,DAI B,MARTIN A,et al.Calcium regulates FGF-23 expression in bone[J].Endocrinology,2013,154(12):4469-4482.
[10] RODRIGUEZ-ORTIZ M E,LOPEZ I,MUÑOZ-CASTAÑEDA J R,et al.Calcium deficiency reduces circulating levels of FGF23[J].Journal of the American Society of Nephrology,2012,23(7):1190-1197.
[11] ECONS M J,MCENERY P T.Autosomal dominant hypophosphatemic rickets/osteomalacia:clinical characterization of a novel renal phosphate-wasting disorder[J].The Journal of Clinical Endocrinology & Metabolism,1997,82(2):674-681.
[12] IMEL E A,PEACOCK M,GRAY A K,et al.Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans[J].The Journal of Clinical Endocrinology & Metabolism,2011,96(11):3541-3549.
[13] IMEL E A,GRAY A K,PADGETT L R,et al.Iron and fibroblast growth factor 23 in X-linked hypophosphatemia[J].Bone,2014,60:87-92.
[14] XIAO Z S,HUANG J S,CAO L,et al.Osteocyte-specific deletion of Fgfr1 suppresses FGF23[J].PLoS One,2014,9(8):e104154.
[15] WU A L,FENG B,CHEN M Z,et al.Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia[J].PLoS One,2013,8(2):e57322.
[16] XIAO L P,ESLIGER A,HURLEY M M.Nuclear fibroblast growth factor 2(FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro[J].Journal of Bone and Mineral Research,2013,28(1):35-45.
[17] HOMER-BOUTHIETTE C,DOETSCHMAN T,XIAO L P,et al.Knockout of nuclear high molecular weight FGF2 isoforms in mice modulates bone and phosphate homeostasis[J].Journal of Biological Chemistry,2014,289(52):36303-36314.
[18] BERGWITZ C,BANERJEE S,ABU-ZAHRA H,et al.Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis[J].The Journal of Clinical Endocrinology & Metabolism,2009,94(11):4267-4274.
[19] KATO K,JEANNEAU C,TARP M A,et al.Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis.Secretion of fibroblast growth factor 23 requires O-glycosylation[J].The Journal of Biological Chemistry,2006,281(27):18370-18377.
[20] TAGLIABRACCI V S,ENGEL J L,WILEY S E,et al.Dynamic regulation of FGF23 by Fam20C phosphorylation,GalNAc-T3 glycosylation,and furin proteolysis[J].Proceedings of the National Academy of Sciences of the United States of America,2014,111(15):5520-5525.
[21] CUI J X,XIAO J Y,TAGLIABRACCI V S,et al.A secretory kinase complex regulates extracellular protein phosphorylation[J].Elife,2015,4:e06120.
[22] RYAN E A,REISS E.Oncogenous osteomalacia.Review of the world literature of 42 cases and report of two new cases[J].American Journal of Medicine,1984,77(3):501-512.
[23] CARPENTER T O,IMEL E A,RUPPE M D,et al.Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia[J].Journal of Clinical Investigation,2014,124(4):1587-1597.
[24] IMEL E A,ZHANG X P,RUPPE M D,et al.Prolonged correction of serum phosphorus in adults with x-linked hypophosphatemia using monthly doses of KRN23[J].The Journal of Clinical Endocrinology & Metabolism,2015,100(7):2565-2573.
[25] KAPELARI K,KÖHLE J,KOTZOT D,et al.Iron supplementation associated with loss of phenotype in autosomal dominant hypophosphatemic rickets[J].The Journal of Clinical Endocrinology & Metabolism,2015,100(9):3388-3392.
京公网安备 11010802041926号